The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech shares surge on success of latest MTD201 study

Wed, 08th Jan 2020 15:51

(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.
The AIM-traded firm said the results demonstrated that 'MTD201' could deliver sustained plasma octreotide concentrations within the range needed for therapeutic efficacy, with an injection interval of six to eight weeks by either subcutaneous or intramuscular administration.

It said those were "key advantages" for patients, payors and physicians over the current standard of care.

The subcutaneous route of administration was said to be simpler, less painful, and would allow the potential for self-administration at home, with less need for hospital visits or nurse supervision to receive treatment.

An extended dose interval would reduce the annual treatment burden for patients from 12 to six injections per year, providing a much less frequent, more cost effective and patient-friendly treatment regimen.

Those attributes were in addition to already demonstrated advantages for MTD201, Midatech said, including less painful injections due to a smaller needle size, simpler and more reliable reconstitution and injection, and the flexibility for unit doses above 30mg.

Study 102 investigated the subcutaneous administration of MTD201 as an additional alternative injection route to intramuscular administration, and determined the preferred administration route to take forward into the MTD201 registration study to begin in mid-2020.

The primary endpoints were to determine the relative plasma octreotide bioavailability and pharmacokinetics of MTD201 deep subcutaneous injection, MTD201 deep intramuscular injection, and 'Sandostatin' octreotide acetate deep subcutaneous injection.

Midatech said the study was conducted in 28 healthy subjects, and following a single injection of MTD201 either subcutaneously or intramuscularly in early October, with all subjects entering a 63-day observation and sampling period to determine plasma octreotide and insulin-like growth factor-1 concentrations.

The company said the key preliminary results from study 102 included that both subcutaneous and intramuscular injections produced a similar overall extended octreotide pharmacokinetic profile.

They also showed that the octreotide release profile supported injection intervals of up to eight weeks, compared to the predominantly four-weekly current standard of care, with inter-subject variability for MTD201 said to be consistent with that observed for currently commercialised long-acting octreotide products.

Looking at its pharmacodynamics, Midatech said the sustained reduction in plasma insulin-like growth factor-1 throughout the 63-day assessment period was similar for both subcutaneous and intramuscular injections.

On its safety, MTD201 was very well tolerated, the company said, with results showing that adverse events were similar for both subcutaneous and intramuscular injections.

There were only minor and transient injection site reactions, with no differences between the injection routes.

Preparation for the start of the next pivotal study for the clinical development for MTD201 was now underway, which was planned to begin later in the first half.

A pivotal registration programme to support a second indication in NET was also expected to start in 2020.

"We are very pleased with the positive results of Study 102. It confirmed both the subcutaneous dosing route for MTD201, as well as the potential for extended dosing intervals," said chief executive officer Craig Cook.

"These are key advantages for patients, physicians and payors, being the first therapy to offer this, and also gives Midatech a competitive advantage versus others as we move the product through to potential approval."

At 1549 GMT, shares in Midatech Pharma were up 54% at 4.24p.
More News
29 Jan 2019 16:56

Midatech Pharma To Raise GBP8 Million, Enters Licence Deal (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC on Tuesday said it entered into conditional agreements to raise GBP8 million by way of a subscription for new ordinary shares at 3.85 pence per on of a

Read more
25 Jan 2019 17:18

LONDON MARKET CLOSE: Stocks Mixed As Miners Rise But Vodafone Sinks

LONDON (Alliance News) - Stocks in London finished the week mixed as commodity miners were unable to keep the FTSE 100 in the green with Vodafone dragging the index lower.The FTSE 100 closed down

Read more
25 Jan 2019 10:40

WINNERS & LOSERS SUMMARY: Earthport Gains As Mastercard Out Bids Visa

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 3.2%. UBS raised the Mexican miner to Buy

Read more
25 Jan 2019 09:51

Midatech Pharma Shares Halve Amid Urgent Scramble To Secure Cash

LONDON (Alliance News) - Shares in Midatech Pharma PLC more than halved Friday as it said it is urgently looking to conclude a deal with a strategic investor with cash funds rapidly running the it

Read more
25 Jan 2019 08:35

Midatech seeking cash after FDA feedback

(Sharecast News) - Oncology and rare disease-focussed company Midatech Pharma announced on Friday that it has received feedback from the US Food and Drug Administration (FDA) on the regulatory study for its lead product, 'MTD201 Q-Octreotide'.

Read more
20 Dec 2018 10:12

Midatech inks evaluation agreement with Asian pharma outfit

(Sharecast News) - Pharmaceutical research and development outfit Midatech has inked an agreement with an unnamed company to evaluate its Q-Sphera drug delivery platform.

Read more
1 Nov 2018 11:37

Midatech Pharma Completes Sale Of US Business To Kanwa Holdings

LONDON (Alliance News) - Immunotherapy-focused pharmaceutical company Midatech Pharma PLC said on Thursday it has completed sale of Midatech Pharma US Inc to Kanwa Holdings LP, owned by Baring for

Read more
8 Oct 2018 15:59

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 9 Octoberno events scheduledWednesday 10 October Whitbread (sale of Costa

Read more
27 Sep 2018 10:44

Midatech Narrows Loss, Agrees Sale Of US Unit For Up To USD19 million

LONDON (Alliance News) - Midatech Pharma PLC reported a narrowed interim loss as it planned to divest its US unit to become a "pure play biotech company".Total revenue for the six

Read more
31 Aug 2018 10:36

WINNERS & LOSERS SUMMARY: Whitbread Surges On Costa Coffee Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 16%. The hospitality firm said it agreed the

Read more
31 Aug 2018 09:38

Midatech Pharma Shares Rise Following Positive MTD201 Trial Data

LONDON (Alliance News) - Shares in Midatech Pharma PLC jumped on Friday following positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201.Shares

Read more
25 Jul 2018 12:26

Midatech Expects 16% Half-Year Revenue Increase Amid Confident Outlook

LONDON (Alliance News) - Midatech Pharma PLC said Wednesday it expects to meet market expectations for 2018 after increasing half-year revenue year-on-year.For the six months to June 30, it

Read more
25 Jul 2018 10:15

Midatech Pharma 'on track' for first half

(Sharecast News) - Cancer-focused pharmaceutical company Midatech Pharma has remained "on track" to deliver financial results for the first half of the calendar year in line with market expectations, and was still exploring options about how to meet its cash flow needs.

Read more
25 May 2018 12:23

Midatech Pharma Commences First In-Human Study Of Brain Cancer Drug

LONDON (Alliance News) - Midatech Pharma PLC said Friday it started the first in-human study of childhood brain cancer drug MTX110.The study will be a combined phase 1 and phase 2 clinical

Read more
3 May 2018 12:14

MidaTech Pharma "Not Aware Of Any Reason" For Sharp Share Price Drop

LONDON (Alliance News) - Midatech Pharma PLC said Thursday that it is "not aware of any reason" behind the sharp drop in its share price.Midatech shares were down 22% at 35.80 its

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.